| Migraine Disorders
Aimovig vs Nurtec ODT
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Aimovig vs Nurtec Odt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNurtec Odt has a higher rate of injection site reactions vs Aimovig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nurtec Odt but not Aimovig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aimovig
Nurtec Odt
At A Glance
SC injection
Once monthly
CGRP receptor antagonist
Oral
As needed or every other day
CGRP receptor antagonist
Indications
- Migraine Disorders
- Migraine Disorders
- Episodic migraine
Dosing
Migraine Disorders 70 mg SC once monthly; some patients may benefit from 140 mg SC once monthly.
Migraine Disorders 75 mg orally as needed; maximum 75 mg per 24-hour period; safety of more than 18 doses in a 30-day period has not been established; may be taken with or without food.
Episodic migraine 75 mg orally every other day, with or without food.
Contraindications
- Serious hypersensitivity to erenumab-aooe or any excipient (reactions have included anaphylaxis and angioedema)
- History of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components, including anaphylaxis and delayed serious hypersensitivity
Adverse Reactions
Most common (>=3%) Injection site reactions, constipation
Serious Hypersensitivity reactions, constipation with serious complications, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity reactions (rash, angioedema, anaphylaxis), constipation with serious complications, oral mucosal ulceration, rash, alopecia, hypertension, Raynaud's phenomenon
Most common Nausea, abdominal pain/dyspepsia
Serious Hypersensitivity including dyspnea and severe rash
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Pharmacology
CGRP receptor antagonist; human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it is an orally administered small molecule that blocks the CGRP receptor implicated in migraine pathophysiology, indicated for both acute and preventive treatment.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aimovig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (1/12)
Nurtec Odt
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (12/12)
UnitedHealthcare
Aimovig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Nurtec Odt
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Aimovig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Nurtec Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Aimovig CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AimovigView full Aimovig profile
Nurtec OdtView full Nurtec Odt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.